MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$218,375K
Net Income
-$51,314K
Net Profit Margin
-23.50%
EPS
-$0.99
Unit: Thousand (K) dollars
Revenue Breakdown
US
Non Us-Royalty And Milestone Rev...
Non Us
Revenue Breakdown
Auvelity
Sunosi
Symbravo
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
218,375
191,203
195,999
170,992
Cost of revenue (excluding amortization and depreciation)
13,564
14,725
12,329
11,912
Research and development
46,227
52,677
48,791
40,162
Selling, general and administrative
208,137
184,996
169,297
150,235
Gain in fair value of contingent consideration
-1,496
590
-9,068
13,185
Intangible asset amortization
1,589
1,572
1,607
1,607
Total operating expenses
268,021
254,560
222,956
217,101
Loss from operations
-49,646
-63,357
-26,957
-46,109
Interest expense, net
-1,540
-1,185
-1,172
-1,120
Gain on debt extinguishment
0
-
0
-
Loss before income taxes
-51,186
-64,542
-28,129
-47,229
Income tax benefit (expense)
128
0
430
-
Net loss
-51,314
-64,542
-28,559
-47,229
Basic EPS
-0.99
-1.26
-0.564
-0.94
Diluted EPS
-0.99
-1.26
-0.564
-0.94
Basic Average Shares
51,799,708
51,198,349
50,653,697
50,021,851
Diluted Average Shares
51,799,708
51,198,349
50,653,697
50,021,851
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
-$51,314K
(-6.96%↓ Y/Y)
US
$215,367K
(47.06%↑ Y/Y)
Non Us
$988K
(-60.68%↓ Y/Y)
Loss before income
taxes
-$51,186K
(-4.60%↓ Y/Y)
Income tax benefit
(expense)
$128K
(112.80%↑ Y/Y)
Product
$216,355K
(45.24%↑ Y/Y)
Non Us-Royalty And
Milestone Revenue
$2,020K
Loss from operations
-$49,646K
(-35.22%↓ Y/Y)
Interest expense, net
-$1,540K
(16.03%↑ Y/Y)
Revenue
$218,375K
(45.54%↑ Y/Y)
Total operating
expenses
$268,021K
(43.51%↑ Y/Y)
Gain in fair value of
contingent consideration
-$1,496K
(81.54%↑ Y/Y)
Selling, general and
administrative
$208,137K
(59.76%↑ Y/Y)
Research and development
$46,227K
(-6.69%↓ Y/Y)
Cost of revenue
(excluding amortization...
$13,564K
(0.86%↑ Y/Y)
Intangible asset
amortization
$1,589K
(0.00%↑ Y/Y)
Buy us a coffee
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)